Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Relapsed/Refractory wAIHA
NCT05922839Phase 2Recruiting
- Sponsor
- Chenmiao
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in warm autoimmune hemolytic anemia (wAIHA), sponsored by Chenmiao. Started Nov 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT05922839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922839.